Apyx Medical Corporation provided earnings guidance for the full year 2022. For the year, the company expects Total revenue in the range of $50.0 million to $63.0 million, representing growth of 3% to 30% year-over-year, compared to total revenue of $48.5 million for the year ended December 31, 2021. Net loss attributable to stockholders in the range of $21.1 million to $12.1 million, compared to net loss attributable to stockholders of $15.2 million for the year ended December 31, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | 0.00% | -3.03% | -38.93% |
09/05 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.93% | 55.43M | |
-2.26% | 187B | |
+2.05% | 110B | |
-1.31% | 69.54B | |
+14.65% | 46.37B | |
-6.69% | 46.05B | |
+7.97% | 42.54B | |
+18.60% | 30.72B | |
+16.92% | 25.62B | |
-6.87% | 23.32B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Provides Earnings Guidance for the Full Year 2022